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Abstract
Background: Spontaneous intracerebral hemorrhage (SIH) accounts for 9 to 25% of all strokes and is associated with a high morbidity and mortality, with 
less than 40% of affected persons surviving 1 year. The condition commonly presents a sudden onset of focal neurological deficits with accompanying 
headache, nausea, vomiting, elevated blood pressure and altered consciousness. Medical treatment commonly includes airway support, blood pressure 
control, management of cerebral edema, symptomatic therapy such as anticonvulsive medication, anticoagulation reversal etc. Different surgical options 
such as open craniotomy, stereotactic aspiration, endoscopic evacuations with or without thrombolysis have also been considered. Most of these techniques 
have already been implemented successfully in the Republic of Moldova. According to the data of the Institute of Neurology and Neurosurgery and the 
Institute of Emergency Medicine for the period 2011-2014, just within these two institutions were performed 137 neurosurgical interventions, including 
67 interventions involving minimally invasive techniques with local fibrilolysis and 70 interventions involving other minimally invasive surgery or 
conventional craniotomy. The obtained results are in concordance with those reported by other European institutions.
Conclusions: The continuous efforts to improve the outcome of SIH during the recent years have led to the development of a variety of minimally invasive 
techniques, most of which have already been adopted by the autochthonous surgeons. New randomized controlled trials are required to establish the 
suitability of these techniques for different clinical situations and SIH localizations. 
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Introduction
Definition. Intracranial hemorrhages can be classified by 
anatomical and etiological aspects. According to anatomical 
aspects, can be distinguished parenchymatous, subarach-
noid, subdural, epidural, supratentorial and infratentorial 
hemorrhages. From etiological point of view, intracranial 
hemorrhages can be further categorized into primary or 
spontaneous and secondary hemorrhages [1,2]. Spontaneous 
intracerebral hemorrhage (SICH) represents blood effusion 
in cerebral parenchyma that is nontraumatic and without any 
known cause of hemorrhage (AVM, cerebral aneurysm or 
tumor). Spontaneous intracerebral hemorrhages (SICHs) are 
considered medical emergencies, commonly having a clinical 
course similar to an intracranial expansive process, with early 
neurological deterioration within the first few hours after 
onset [3.5]. Based on their location, supratentorial  SICHs 
can be further divided into lobar or superficial (situated in 
cortical and subcortical areas of frontal, temporal, parietal and 
occipital lobes) and central or deep (localized in the areas of 
nucelus caudatis, globus pallidus, thalamus, internal capsule, 
white periventricular substance or cerebral ventricles), while 
infratentorial SICHs can involve the cerebellum, pons and the 
brain stem. About 1/3 of SICHs have lobar localizations, and 
about 2/3 of SICHs have bazal or infratentorial localizations 
[2,6,7]. Overall, supratentorial  SICHs represent over 80% of 
all SICHs [8,9]. According to the results of STICH (Surgical 
Trial in Intracerebral Hemorrhage) trial, about 39-40% of 
supratentorial SICHs were lobar, 42% were deep (involving 
basal ganglia and thalamic nuclei), 17-19% had mixed loca-
tions and 1% could not be evaluated [10]. 
 Epidemiology. Worldwide incidence varies between 10 
and 40 cases per 100,000 population and increases with age [4, 
11, 12]. The pathology affects a substantial proportion of the 
population in Europe and worldwide, representing 9-27% of 
all strokes [262]. Studies performed in the last decade indicate 
that SICH represents 10-15% of all strokes in Europe, USA 
and Australia, 20-30% of strokes in Asia [June 13-17], about 
10% of strokes in high-income countries and 20% of strokes 
in middle and low-income countries [18, 19].
 It is also known that intracerebral hematomas represent 
the third leading cause of death after cardiovascular diseases 
and cancers, accounting for 12.5 to 15% of overall mortality 
and being a major cause of disability. Reported mortality 
during the first month after SICHs varies between 30-59%, 
with an overall survival of less than 40% at 1 year and less 
than 20% at 10 years [13, 17, 20-23]. Among the survivors, 
disability reaches 70-80% [2, 3, 24], with only 10% of patients 
becoming functionally independent at 1 month and about 
20% at 6 months [12, 17, 20, 25, 26].
 Etiology, pathogenesis and pathophysiology. Predis-
posing factors for SICHs include modifiable risk factors 
(hypertension, diabetes, alcohol abuse, smoking, poor diet, 
obesity, anticoagulation therapy, previous stroke, illicit drugs 
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consumption, especially cocaine) and non-modifiable risk 
factors (male sex, age, ethnicity - African or Asian, genetic 
predisposition, brain amyloidosis, various coagulopathies). 
The main risk factors (male sex, age, hypertension, alcohol 
abuse, smoking, diabetes, poor diet, abdominal obesity and 
physical inactivity) account for over 80% of the overall risk 
of stroke worldwide [18, 27]. Association of additional risk 
factors, such as high serum level of certain apolipoproteins, 
increases the risk up to 90% [27]. Most authors agree that from 
all risk factors, the most important are hypertension and ce-
rebral amyloid angiopathy [1, 2, 15, 17, 28, 29]. Thus, chronic 
hypertension is responsible for 50-70% of all SICHs [15, 17, 
30]. The disease leads to small structural changes of the brain 
vessels, being associated with atherosclerosis, lipohialinosis 
and formation of micro aneurisms. A variety of risk factors 
can also lead to so-called small brain vessel disease, which is the 
underlying pathology in many cases of SICHs. The prevalence 
of cerebral small vessel disease in general population increases 
with age and also leads to progressive cognitive changes and 
vascular dementia [2, 6, 15, 18, 26, 29].
 As the brain hematoma expands, it increases local pressu-
re affecting the brain tissue and tearing adjacent vessels. Coa-
gulation disorders and hypertension predispose to rebleeding 
in the early stages. The mass effect of the hematoma further 
increases intracranial pressure, causing significant damage to 
adjacent brain structures and also affecting distant regions by 
shifting the midline structures to the contralateral side and 
even resulting in various degrees of brain herniations. If the 
circulation of cerebrospinal fluid is disturbed, hydrocephalus 
occurs [18, 31, 32].
  Pathophysiological changes of supratentorial SICH were 
studied in detail clinically and experimentally [29, 32, 33]. 
Mechanical compression of local microcirculation with sub-
sequent release of vasoconstrictor substances from hematoma 
causes a marginal zone of ischemia called secondary or perile-
sional ischemia. Various terms such as “ischemic penumbra” 
or “tissue at risk” have been proposed to describe this altered 
functional brain area, but potentially recoverable [20, 29, 32-
35]. Some authors suggest that perilesional hypoperfusion is 
rather a consequence of reduced metabolic demand than a 
true tissue ischemia [6, 14]. Various degrees of perilesional 
hypoperfusion with or without “spot” sign on CT angiography, 
have been reported in about 60% of patients with acute SICH 
[36]. That’s why the reason for surgical treatment in SICHs is 
not only to eliminate the mass effect, but also to reduce the 
toxic effects of blood components for potential brain tissue 
recovery in the ischemic penumbra [29, 32, 37, 38].
Another pathogenic factor is related to the brain edema, 
which increases over several days, leading to mass effect and 
raised intracranial pressure, secondary neuronal damage and 
neurological deterioration. Disruption of the blood-brain 
barrier and serum protein leakage into extracellular space is 
followed by an increase in osmolarity and release of biolo-
gically active substances (arachidonic acid, histamine) with 
associated development of vasogenic edema (extracellular). 
Disruption of the energy metabolism of the cell membranes 
and cellular wall pumps leads to fluid shift into the cells 
and development of cytotoxic edema (intracellular). In the 
subsequent phase, the lysis of red blood cells with release of 
hemoglobin metabolites, inflammatory cytokines, matrix 
metalloproteinases, iron and thrombin triggers generation 
of free radicals with associated inflammatory, neurotoxic and 
apoptotic effects [15, 20, 29, 32, 33, 35]. Perilesional edema 
peaks at 72 hours and usually persists for 5 days, although it 
may persist for up to 2 weeks [2, 6, 20].
Re-bleeding, hematoma expansion and intraventricular 
eruption are major predictors of death in the acute phase of the 
SICHs or severe disabilities in survivors [4, 5, 14, 16, 39-43]. 
Intraventricular extension occurs in 30-45% of patients with 
SICHs, depending on the size and location of the bleeding 
[3, 17, 26, 30, 32, 41, 44]. The overall mortality in patients 
with intraventricular hemorrhage is 5 times higher than in 
patients with isolated SICHs [45]. Since the rigid shape of the 
skull limits the ability of volumetric expansion of its content, 
hematomas with a volume exceeding 150 ml inevitably lead 
to death [18]. Hematoma growth is also associated with in-
creased mortality and poor functional outcomes, regardless 
of its initial volume or other associated factors.
 Three definitions have been used to define the growth of 
SICHs: (1) any increase in size of SICH, (2) an increase of ≥ 
33% or ≥ 12.5 ml and / or (3) interval radial increase in size 
over 1 mm confirmed at computed tomography (CT) at 24 
hrs compared with the original CT [39, 46]. Identification of 
techniques for predicting the expansion of SICHs remains a 
priority of many research studies [21, 47]. Among the pro-
posed methods for estimating the probability of hematoma 
growth can be mentioned determination of density and 
hematoma shape at CT scanning [18, 46] or the presence of 
the “spot” sign on CT angiography [18, 36, 47, 48]. According 
to the published results, heterogeneous density on CT inde-
pendently predicts expansion of SICH, the irregular shape of 
hematoma being also associated with its expansion [48]. The 
presence of the “spot” sign on CT angiography represents ano-
ther independent predictor of hematoma expansion, increased 
mortality and a poor prognosis [36, 47]. In addition, the “spot” 
sign allows patient selection for individualized therapeutic 
regimens such as administration of early hemostatic treatment 
(recombinant activated factor VII), more aggressive reduction 
of blood pressure and / or surgical interventions [36].
 Staging of intraparenchimal hemorrhage. SICH is 
not a monophasic event and includes three distinct phases: 
(1) initial hemorrhage, (2) expansion of the hematoma and 
(3) perihematomal edema [14, 42]. Disease progression and 
subsequent results are influenced primarily by two factors: 
hematoma expansion and cerebral perihematomal edema. 
After the initial bleeding, hematoma reaches its maximum size 
in 15-20 minutes, even though occasionally the bleeding may 
continue for up to 6 or even 24 hours. Elucidating the cause 
of hematoma expansion (on-going bleeding or re-bleeding 
from one or more vessels) confirmed by CT is particularly 
useful for selecting the treatment strategy [6, 14].
 Histologically can be distinguished 5 phases of intra-
parenchymal hematomas that are based on cellular changes 
during the process of degradation and absorption of blood 
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products. These phases are also distinguished at brain MRI 
as follows: hyperacute phase (from onset to 12 hours), acute 
phase (from 12 hours to 2 days), early subacute phase (from 
2 to 7 days), late subacute phase (from 8 days to one month) 
and chronic phase (after one month) [49].
Clinical picture
 Symptoms of SICHs can be divided into general and 
focal. The clinical manifestations  may vary depending on 
hematoma location, size and eruption into the ventricular 
system [1, 4, 5, 12, 14, 30, 41]. The onset is usually sudden with 
headache, vomiting, seizures and / or development of focal 
neurological deficits. In the acute phase can be encountered 
alterations of consciousness (from sleepiness to coma), signs 
of meningeal irritation, motor deficits (hemiparesis, hemi-
plegia), dysmetria, cranial nerve palsy (especially involving 
oculomotor nerve), various autonomic dysfunctions, etc [4, 6, 
12, 18, 30, 50]. Depending on the affected brain regions, the 
clinical presentation can range from minor neurological de-
ficits to fatal herniation syndromes resulting from hematoma 
expansion, prominent mass effects and increased intracranial 
pressure [42]. Although the clinical picture alone is insuffici-
ent to reliably differentiate SICHs from ischemic strokes [14, 
30, 50], it maintains its relevance for prompting imaging and 
laboratory investigations as well as for initiating a treatment 
plan, taking into account the fast dynamics of SICHs.
 For obtaining a consensus among institutions, a better 
communication and a more accurate assessment of neurologic 
status and its dynamics, a number of neurological deficit scales 
and functional status scores have been adopted internationally. 
Among the most common can be listed: Glasgow Coma Scale 
(GCS) is the most common scoring system used to describe 
the level of consciousness in a person with brain injury. It is 
composed of three parameters (best eye opening, best motor 
response and best verbal response), the overall score varying 
between 3 and 15 (Table 1). A score of 13 or higher correlates 
with a mild brain injury, a score of 9 to 12 correlates with a 
moderate injury, and a score of 8 or less correlates with a 
severe brain injury. A diagnosis of coma corresponds to a 
Table 1
Glasgow Score(GCS)
Compo-
nents Grading Points
Eye 
opening
Does not open eyes, even under pressure 1
Opens eyes in response to painful stimuli 2
Opens eyes on verbal command 3
Opens eyes spontaneously 4
Motor 
responce
No response 1
Extension to painful stimuli (decerebrate 
response)
2
Abnormal flexion to painful stimuli (decorticate 
response)
3
Flexion / Withdrawal to painful stimuli 4
Localizes painful stimuli 5
Obeys commands 6
Verbal 
responce
Makes no sounds 1
Incomprehensible sounds 2
Utters inappropriate words 3
Confused, disoriented 4
Oriented, converses normally 5
Table 2
ICH score and ICH-GS score [53] 
Components
ICH-GS Score ICH Score
Grading Points Grading Points
Age (years)
< 45 1 < 80 0
45 - 64 2 ≥ 80 1
> 65 3
GCS (points)
13 - 15 1 13 - 15 0
9 - 12 2 5 - 12 1
3 - 8 3 3 - 4 2
ICH Localization 
Supratentorial 1 Supratentorial 0
Infratentorial 2 Infratentorial 1
IVH
Yes 1 Yes 0
No 2 No 1
ICH Volume (ml)
<30 0
≥30 1
Supratentorial ICH volume (ml)
< 40 1
40 - 70 2
> 70 3
infratentorial ICH volume (ml)
< 10 1
10 - 20 2
> 20 3
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score below 7-8. The summation to provide an overall score 
for coma (from 3 to 15) results in some loss of information, 
but still proves valuable for a variety of purposes, including 
triage and epidemiological studies [45, 51].
ICH (intracerebral hemorrhage) score, original and 
modified, represents reliable grading scales for patients with 
intracerebral hemorrhage evaluated at presentation, allowing 
risk stratification and predicting the mortality in the first 30 
days. The ICH scale uses such factors as age, volume of ICH, 
GCS score and presence of intraventricular hemorrhage (Table 
2). Scale range is between 0 and 6 points. Higher ICH scores 
are associated with increasing mortality during the first month 
– all patients with a score 0 survive and all patients with a score 
greater than or equal to 5 die within 30 days [6, 42, 52, 53]. 
ICH-GS Score (intracerebral hemorrhage-grading scale) 
developed for SICHs, appears to possess greater sensitivity 
in predicting in-hospital mortality, mortality at 30 days and 
post-therapy functional results compared with the original 
ICH score (Table 2) [53]. 
FUNC score is another prediction tool for risk stratifi-
cation and functional outcome at 90 days after stroke [42]. 
FUNC score ranges from 0 to 11 based on the volume of ICH, 
age, location of ICH, GCS and cognitive dysfunction (Table 
3) [42]. For each patient with ICH, a particular FUNC score 
value corresponds to the percentage probability of attaining 
functional independence (Glasgow Outcome Score greater 
than or equal to 4) at 90 days. A higher score is associated 
with a greater likelihood of functional independence, defined 
as GOS ≥ 4 at 90 days. No patients with a FUNC score ≤ 4 
reach functional independence and more than 80% of patients 
with FUNC score of 11 achieve functional independence at 
90 days. However, only scores at the extreme ends appear 
to be clinically useful, while the average scores have a lower 
predictive value [42].
Table 3
FUNC Score [42]
Components Grade Points
ICH Volume (cm3)
< 30 4
30 - 60 2
> 60 0
Age (years)
< 70 2
70 - 79 1
≥ 80 0
ICH Localization
Lobar 2
Deep 1
Infratentorial 0
GCS (points)
≥ 9 2
≤ 8 0
Pre-ICH cognitive impairment 
No 1
Yes 0
Total FUNC Score 0 - 11
Rankin Scale is a commonly used scale for measuring 
the degree of disability or dependence in the daily activities 
in patients with stroke or other acute neurological disabili-
ties. The scale was developed in 1957 and modified in 1988. 
The modified Rankin scale ranges between 0 and 6, running 
from perfect health without symptoms to death: 0 - without 
symptoms; 1 - no significant disability; able to carry out all 
usual activities, despite some symptoms; 2 - mild disabilities; 
able to look after own affairs without assistance, but unable 
to carry out all previous activities; 3 - moderate disabilities; 
requires some help, but able to walk unassisted; 4 - moderately 
severe disabilities; unable to walk without assistance or to care 
unassisted to own bodily needs; 5 - severely disabled, bedrid-
den, incontinent and requiring constant care; 6 - dead [54, 55].
Barthel Index evaluates 10 basic activities of daily living, 
which include: (1) feeding,  (2) bathing (3) grooming (washing 
face, combing hair, brushing teeth), (4) dressing ( 5) bowel 
control (6) bladder control, (7) the ability to use the toilet, (8) 
chair transfer, (9) ambulation (10) stair  climbing. The total 
score ranges between 100 points (independent) and 0 points 
(completely dependent) [54, 56].
GOS score (Glasgow Outcome Score) is a scale for asses-
sing the final state after an acute brain disease. Depending 
on their recovery, the patients are grouped into 5 categories: 
(1) good recovery with resumption of normal life des-
pite minor deficits, (2) moderate disability, but relatively 
independent without needs for assistance in everyday life 
(employment is possible but may require special equipment), 
(3 ) severe disabilities – conscious, but dependent for daily 
support, (4) persistent vegetative state with prolonged periods 
of unresponsiveness or minimal responsiveness (5), deceased 
[45, 52, 54]. The correlation between ICH score and  GOS 
score is negative and statistically significant [52].
Paraclinical diagnosis
Neuroimaging studies are vital to elucidate the diagnosis 
and etiology of SICHs [4, 6, 42, 57]. Brain imaging is the 
cornerstone for diagnosing SICHs because hemorrhagic and 
ischemic strokes can not be differentiated by clinical data alone 
[4, 6, 42, 57]. Neuroimaging studies are needed not only for 
diagnosis, but also provide valuable information related to the 
type of bleeding, its etiology and pathophysiology [4, 49, 57]. 
Neuroimaging studies include a compulsory brain CT scan-
ning, an optional brain MRI followed by angiography of the 
cerebral vessels obtained by CT and / or MRI [4, 5, 18, 33, 58]. 
 Brain CT is the investigation of choice for the diagnosis 
of SICHs, able to establish the diagnosis within minutes from 
the onset of symptoms and to provide additional details such 
as the bleeding size and localization. Non-contrast CT remains 
the “gold standard” for diagnosis, although a variety of new 
neuroimaging techniques can provide additional information 
related to pathophysiology of SICHs and their prognosis in 
individual patients [3, 5, 6, 30, 42]. Brain CT also enables 
rapid calculation of the volume of bleeding, which may be 
performed by two methods: the “ellipse” method based on 
routine CT images and the planimetric method using the 
neuronavigation station equipment [59]. CT angiography in 
hyperacute phase, followed by a post-contrast scan can also 
identify the “spot” sign – one or more hyperintense spots in 
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hematoma caused by the leak of contrast material into its 
cavity. Its presence is an independent predictor associated in 
60% of cases with hematoma expansion and a reserved pro-
gnosis [4, 18, 35, 41, 47, 48]. Carotid angiography is performed 
when the cause of the bleeding remains equivocal or when a 
vascular malformation is suspected.
MRI identifies SICHs shortly after their onset [5, 6, 18, 42, 
49], being also reliable for detecting chronic iron deposits related 
to previous bleedings [6, 18, 42, 49]. MRI is especially indicated 
when the clinical picture and cerebral CT exams cannot establish 
the final diagnosis or the etiology of bleeding [14, 18, 42, 49]. 
Initial MRI can be also performed as part of prognostic score 
protocols for predicting clinical outcomes in acute SICHs [18, 
30]. Micro-hemorrhages detected by MRI can be occasionally 
useful in elucidating the pathophysiology and development 
of SICHs. Recent studies indicate that transcranial ultrasound 
has an excellent correlation with cerebral CT for evaluating the 
degree of bleeding in patients with hyperacute SICHs, therefore 
the modality can be also considered for early diagnosis and non-
invasive monitoring of SICHs [60].
Due to the rapid advances in the field of medical imaging 
during the last decade and the absence of a standardized 
international protocol related to SICHs imaging [3, 18, 50], 
the imaging modalities and employed protocols for managing 
SICHs may vary considerably across different countries. In 
most institutions, CT is recommended as a standard imaging 
procedure for differentiating hemorrhagic from ischemic 
strokes. CT angiography is performed immediately in case 
of suspected aneurismal hemorrhages. In general, a younger 
age and a lobar location of SICH without pre-existing hyper-
tension require a wider variety of diagnostic investigations 
beyond the initial cerebral CT [18, 61]. The relevance of 
other investigations such as MRI angiography may depend 
upon the clinical situation, the choice being also affected by 
local resources and recommended protocols by the national 
healthcare systems [18]. 
Management
While the search for a specific targeted therapy for SICHs 
continues, excellent medical care likely has a potent, direct 
impact on morbidity and mortality even now, before a specific 
therapy is found [3]. Current treatment is targeting a variety of 
components such as preventing hematoma expansion, redu-
cing the mass effect, minimizing brain injuries and preventing 
secondary neurological and nosocomial complications [4, 29]. 
Hospital admission is mandatory, preferably in a specialized 
neurosurgical department. If such facilities are not available, 
admission to a Neurology department is also acceptable [18]. 
Before admission, the treatment is directed at providing basic 
airway and breathing support, blood pressure control and he-
modynamic stabilization, lowering the intracranial pressure, 
monitoring vital signs etc. [3, 5, 6, 29, 41].
Medical treatment
Medical management is initiated immediately and conti-
nues in the intensive care unit, including cardio-respiratory 
and blood pressure control, reversal of coagulation defects, 
cerebral edema, intracranial hypertension and seizure mana-
gement, addressing the risk factors and associated medical 
conditions etc [15, 17, 26 62]. Most studies show superior 
results for patients admitted into an intensive care unit, pre-
ferably of neurological or neurosurgical profile [5, 6, 18, 63]. 
Patients with a low level of awareness often require ventilatory 
support [29]. Although the treatment may vary depending on 
the patient’s condition, it also addresses a number of general 
principles such as blood pressure control, management of 
coagulation deficiencies, management of cerebral edema and 
elevated intracranial pressure, neuroprotective therapy etc [4, 
5, 35, 41, 63, 65].
Management of coagulation deficiencies. Congenital or 
acquired coagulation factor deficiencies worsen the prognosis 
for SICHs by increasing the rate of hematoma expansion as 
well as by affecting its subsequent resorption [4, 6, 41]. Pati-
ents at risk also include those taking oral anticoagulants and 
those with qualitative or quantitative platelet abnormalities. 
Recognition of the underlying coagulopathy allows developing 
a treatment strategy. For  example, in patients with thrombo-
cytopenia or a coagulation factor deficiency, administration of 
platelets or the appropriate deficient factor is indicated [2-4, 6, 
41]. Acquired coagulopathy may be attributed to longstanding 
liver and/or renal disease, malignancy, or medication. For pa-
tients being treated with oral anticoagulants, the medications 
are immediately canceled and specific antidotes are adminis-
tered to correct the international normalized ratio (INR) as 
rapidly as possible [4-6, 14, 41]. Infusions of vitamin K and 
fresh-frozen plasma (FFP) have usually been recommended 
for this purpose, but more recently, prothrombin complex 
concentrates (PCCs) and recombinant factor VIIa (rFVIIa) 
have emerged as potential therapies [3]. Concominant use of 
vitamin K with FFP, cryoprecipitate, or clotting factor concen-
trates can be also used to hasten reversal of oral anticoagulants. 
Even in patients without any coagulation deficiencies, admi-
nistration of various hemostatic agents such as aminocaproic 
acid, tranexamic acid and recombinant activated factor VII 
has been proposed [5, 18, 63]. Although their routine usage in 
patients without coagulation deficiencies was associated with 
enhanced hemostasis and reductions in hematoma growth, 
the medication did not alter severe disability or mortality 
rates [14, 35, 41]. 
Management of hypertension. Arterial hypertension is 
associated with hematoma expansion and poor prognosis, 
although a clear causal effect has not been established [4, 14, 
35, 41, 64]. Current guidelines suggest aggressive reduction 
of systolic blood pressure (BP) with intravenous infusion of 
vasoactive drugs (labetalol, esmolol and nicardipine) only if 
systolic BP is over 180 mm Hg and/or mean BP is over 130 
mm Hg [3-5, 64]. Given the altered cerebral perfusion, the 
blood pressure reduction should be also gradual, most authors 
suggesting reducing systolic BP just below 160 mm Hg and/or 
mean BP just below 110 mm Hg as an initial step [3, 4, 64]. The 
Antihypertensive Treatment of Acute Cerebral Hemorrhage 
(ATACH) I Trial, a multi-center prospective study performed 
during 2004-2008 to determine the appropriate level of systolic 
45
REvIEw ARTIClES
46
Curierul medical, February 2016, Vol. 59, No 1
BP reduction with intravenous nicardipine infusion for 18 to 
24 hours postictus in subjects with intracerebral hemorrhage 
who are present within 6 hours of symptom onset, showed 
that the treatment was well tolerated and reduced the risk of 
hematoma expansion, neurological deterioration and hospital 
mortality [6, 14, 35]. The results of the Intensive Blood Pre-
ssure Reduction in Acute Cerebral Hemorrhage (INTERACT) 
I randomized trial also suggested that early intensive blood 
pressure reduction to systolic values  ≤ 140 mmHg initiated 
within 6 hours of symptom onset appeared to attenuate he-
matoma expansion in patients with intracerebral hemorrhage. 
In subgroup analyses, patients recruited within 3 hours and 
patients with an initial SBP ≥181 mm Hg appeared to have the 
greatest benefit with intensive blood pressure reduction [14, 
35, 66]. The INTERACT-2 trial found that intensive blood 
pressure lowering in patients with intracerebral haemorrhage 
reduced the risk of major disability and improved the chances 
of recovery by as much as 20%, even though no changes in 
mortality rates were reported [14, 66, 67].  A variety of new 
studies are also underway. One such trial is the perioperative 
antihypertensive treatment in patients of spontaneous intrace-
rebral hemorrhage (PATICH) trial, which aims to determine if 
the intensive preoperative BP reduction improves the overall 
prognosis and the postoperative outcome [68].
Cerebral edema and intracranial hypertension manage-
ment. The Intracranial hypertension is an important cause of 
secondary brain injuries. Elevation of the head of the bed to 
about 30° promotes displacement of cerebrospinal fluid from 
the intracranial compartment to the spinal compartment. 
Medical management can also include sedation, analgesia, 
osmotherapy with either mannitol or hypertonic saline, 
controlled transient hyperventilation as well as drainage of 
cerebrospinal fluid depending on the degree of intracranial 
hypertension [3, 4, 41, 50, 64, 66]. Even though randomized 
clinical trials have failed to demonstrate a significant benefit 
of bolus therapy with mannitol on cerebral blood flow and 
mortality rates [5, 20, 35], monitoring of intracranial pressu-
re is commonly associated with better functional results in 
patients with SICHs [23]. Intracranial pressure monitoring 
and its maintenance within 50-70 mm Hg is especially  in-
dicated in patients with a GCS score < 8 and/or evidence of 
brain herniation, significant intraventricular hemorrhage and 
hydrocephalus. 
Anticonvulsant therapy. Seizures are reported in 4-8% 
of patients with SICHs, and are more prone to occur in lobar 
(superficial) hematomas: about 4.2% of cases occur in the first 
24 hours and about 8.1% - within 1 month after the onset of 
SICHs [2, 4, 14]. Their presence is commonly associated with 
higher rates of complications, increased mortality, and poor 
functional outcomes in survivors [69]. Seizures in SICHs are 
usually treated with intravenous administration of loraze-
pam (0.05–0.10 mg/kg) followed by an intravenous loading 
dose of phenytoin or fosphenytoin (15–20 mg/kg), valproic 
acid (15–45 mg/kg), or phenobarbital (15–20 mg/kg). The 
anticonvulsant therapy can be discontinued if no seizures are 
noted for one month. Although, no randomized trials have 
addressed the efficacy of prophylactic antiepileptic medicati-
on in SICHs, the option may be considered for patients with 
lobar hematomas and higher risks for seizures [3, 20, 35, 41, 
50, 69]. In addition, 24-hrs electroencephalography (EEG) 
monitoring should be considered for patients with reduced 
consciousness and depressed mental status out of proportion 
to the degree of brain injury [3, 5, 35, 41].
Deep venous thrombosis prophylaxis. Immobilized 
state and paresis predispose SICHs patients for deep vein 
thrombosis and pulmonary embolism. The reported inci-
dence of symptomatic venous thromboembolism in SICHs 
varies between 0.5% - 13%, and that of pulmonary embolism 
between 0.7% - 5% [41]. Intermittent pneumatic compressi-
on devices and elastic stockings are indicated and should be 
placed on admission on all immobilized patients. Low doses 
of unfractionated heparin or low-molecular-weight heparins 
can be considered in patients with hemiplegia, 3-4 days after 
the onset of SICHs and after ensuring that the intracerebral 
bleeding stopped [2-5, 35, 50]. 
Glycemic control. Hyperglycemia has a deleterious effect 
on cerebral ischemia, being associated with increased mortali-
ty and reduced rates of early functional recovery [5, 14, 23, 70]. 
Even though studies performed in SICHs patients suggest that 
early glycemic control can improve the outcome [5, 26, 70], 
there is growing evidence that “enhanced” glycemic control 
(<2.8 mmol/l or <50 mg/dL) obtained by insulin infusions in 
patients with acute brain injury may be associated with signi-
ficantly reduced concentrations of extracellular glucose in the 
brain [5, 14, 70]. Because of this, many clinicians are reluctant 
to lower serum glucose if the level is below 10.0 mmol/l (180 
mg/dL) [14, 70]. At the moment the optimal management of 
hyperglycemia in SICHs and the target glucose levels remain 
to be clarified; however, hypoglycemia should be avoided [3]. 
Neuroprotection. The goal of neuroprotective agents 
(such as magnesium, minocycline, deferoxamine) is to favo-
rably influence the cascade of biochemical events triggered 
by the intracerebral hemorrhage, subsequently leading to 
neuronal deterioration an cell death [35]. Various neuropro-
tective management strategies have been studied in SICHs 
[71]. Although the results suggest that neuroprotective agents 
may provide incremental improvements, new trials are re-
quired to further elucidate their effects and to define their 
clinical indications [71]. Hypothermia has also been studied 
among the neuroprotective strategies in patients with ischemic 
and hemorrhagic strokes. Thus, a pilot study of therapeutic 
hypothermia in patients with SICHs reported reduction in 
cerebral edema and perihematomal inflammation [5, 35]. 
Several other clinical studies, however, showed incremental or 
little benefits for patients with SICHs treated with NXY-059, 
mannitol, glycerol, and citicoline [5, 35, 66, 72]. 
Surgical treatment
Surgical management of SICHs may be required in many 
clinical situations such as intracranial hematomas greater than 
3 cm, a structural vascular lesion or lobar hemorrhage in a 
young patient, increasing intracranial pressure with neuro-
logical deterioration, etc. A variety of procedures including 
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conventional open craniotomy, simple aspiration, ventricu-
lostomy, endoscopic evacuation, stereotactic aspiration with 
local fibrinolysis or various combinations have been used for 
this purpose [20, 35]. However, the decision about whether 
and when to surgically remove the hematoma and the type 
of procedures to be used still remain controversial. Surgical 
evacuation of SICHs is aimed at reducing the mass effect, 
decreasing intracranial pressure, improving of regional blood 
flow, minimizing the release of blood degradation products, 
minimizing cerebral edema and secondary brain injury [5, 
29, 64]. The interval from the initial onset of SICHs is com-
monly divided into 3 stages: ultra-early (less than 7 hours), 
early (from 7 to 24 h) and delayed (over 24 hours) [73]. Most 
studies indicate that early stage (7-24 hours) appears the op-
timal time for surgical interventions [73], while ultra-early 
brain surgery (within first 4 hours of symptom onset) is often 
associated with higher rates of rebleeding [73, 74]. The em-
ployed surgical techniques used in the evacuation of SICHs 
can be grouped into several categories such as evacuation by 
conventional craniotomy, evacuation by endoscopy, evacua-
tion via stereotactic techniques and aspiration methods with 
local fibrinolysis [1, 3, 63, 75].
Conventional craniotomy involves removing a portion of 
the skull (a bone flap ranging from about 5x5cm to 10x10cm 
in size) and conducting open surgery to drain the hematoma 
and repair the ruptured blood vessel. This represents a major 
surgical procedure that is typically used when the hematoma 
is very large, or when it is compressing the brain stem or 
other centers that control vital functions. Hematoma cavity 
is cleared and a hemostatic sponge can be applied if needed. 
The cavity is also drained and the bone flap is fixed. In cases 
of severe cerebral edema or prolapsing cortex through the 
surgical wound, the bone flap can be temporarily preserved 
in the subcutaneous fat of the abdominal region (for later use 
to close the skull defect). 
Evacuation via endoscopy involves drilling a small 
burr hole in the skull and draining the hematoma using an 
endoscope. It represents an advanced technique that allows 
simultaneous monitoring of intracranial pressure and using a 
variety of instruments for microsurgery such as an operating 
microscope, laser and ultrasound equipment for clot lysis and 
aspiration etc. A supraorbital approach through an eyebrow 
incision has been frequently used for this purpose, being ori-
ginally described by Justin et al in 2012 [31]. The method is 
particularly useful for anterior basal ganglia hematomas that 
are usually elongated in shape, allowing an optimal trajectory 
along their longitudinal axis with a complete evacuation after 
a single pass of the endoscopic tube [31]. Other endoscopic 
approaches may involve using small burr holes on coronal 
suture for accessing anterior basal ganglia hemorrhages, or in 
the parietal-occipital region for accessing basal ganglia and 
thalamus. In superficial lobar SICHs, a small burr hole can 
be applied just above the hematoma in its closest proximity 
to the surface [31].
Stereotactic evacuation represents an advanced technique 
that uses a special stereotactic frame for immobilizing the 
patient’s head. The technique allows a preliminary compu-
ter calculation of the puncture route and a greater degree 
of precision and accuracy than otherwise possible. Apart 
from aspirating the content of the hematoma, the method 
also allows ultrasound clot lysis or local administration of 
fibrinolytic agents (streptokinase, urokinase, recombinant 
APT etc) [3, 37].
Puncture and aspiration with local fibrinolysis uses CT 
for guidance and includes several steps: 1) applying a burr hole 
according to the automatically calculated puncture site and 
catheter trajectory based on CT data, 2) guiding the puncture 
cannula into hematoma cavity according to the calculated 
trajectory, 3) aspiration of the liquid part of hematoma and 
application of a special catheter in the hematoma cavity for 
subsequent infusion of thrombolytic agents to enhance clot 
drainage [63, 74, 76, 77]. Local fibrinolysis and aspiration of 
the remaining content is then carried out in the postoperative 
period. A major advantage of this technique is the possibility 
of being carried out within 20 minutes under local anesthesia 
in the emergency department relying on a routine brain CT 
scan [78]. In many institutions, a special navigation system 
that allows calculating the optimal puncture site and catheter 
trajectory based on CT data is integrated into the CT angi-
ography scanner for convenience. The catheter can be also 
inserted under the fluoroscopic guidance and its placement 
is evaluated by a post-procedural CT scan [79].
Early studies have failed to demonstrate superior outcomes 
following conventional craniotomy in supratentorial SICHs 
compared with best medical therapy [5, 16, 80, 81]. This 
resulted in a more conservative attitude and application of 
tighter selection criteria for surgical interventions in SICHs 
[13]. The increasing requirements for convincing evidence 
in clinical decision making led to the initiation of STICH 
(Surgical Trial in Intracerebral Haemorrhage) trial, the lar-
gest prospective randomized study that was conducted in 83 
centers across 27 countries. The study was initiated in 1995 
and the final results were published in 2005, concluding that 
in cases where surgical intervention is not heavily favored 
by current clinical judgement, early clot evacuation does not 
offer clinical benefit over conservative management [6, 10, 66]. 
Thus, after 6 months of follow up, 26% of surgically treated 
patients versus 24% of patients treated with medication had 
a favorable outcome. The trial results affected the clinical de-
cision making and surgical interventions were employed less 
frequent [82]. Noteworthy, however, is that in STICH trial less 
than 25% of surgeries were minimally invasive [5, 10, 66, 83, 
84]. The subgroup analysis of the STICH trial also revealed 
that patients with lobar superficial hematomas (≤1 cm from 
the brain surface) without intraventricular hemorrhage who 
underwent surgery had a more favorable outcome, about 49% 
of them demonstrating positive results (representing an 8% 
absolute increase in good outcomes compared with similar 
subjects in the medical arm). This subgroup of patients was the 
target of the STICH II study, an international, parallel-group 
trial undertaken in 78 centers in 27 countries, comparing early 
surgical hematoma evacuation within 12 hrs of randomization 
plus medical treatment versus initial medical treatment alone 
(later evacuation was allowed if judged necessary) [3, 6, 84]. 
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The results of STICH II trial confirmed that early surgery 
does not increase the mortality or disability at 6 months and 
might have a small but clinically relevant survival advantage 
for patients with superficial SICHs without intraventricular 
hemorrhage, the greatest benefits being obtained in patients 
with GCS between 9-12 [5, 66, 83, 84]. Other studies and meta-
analyses also confirmed the benefits of surgical interventions 
for superficial SICHs compared to conservative management 
alone [10].
The continuous search to improve the outcomes of SICHs 
has lead to the development of minimally invasive techniques. 
During the last decade, a variety of techniques of minimally 
invasive surgery, including endoscopic neurosurgery and 
stereotactic aspiration have emerged and are widely used for 
treating supratentorial SICHs. Among the advantages of mi-
nimally invasive methods can be listed: 1) significantly lower 
invasiveness and the possibility of being applied earlier than 
the standard surgical treatment 2) reduced operation time, 
3) the option of being performed under local anesthesia, and 
4) reduced brain trauma, especially for deep lesions [50, 66]. 
Recent studies showed that clot reduction with minimally 
invasive surgery plays an important role in limiting brain 
edema, reducing cellular damage and neurological deficits 
after SICHs [40, 85]. A meta-analysis published in 2012, re-
ported that patients with supratentorial SICHs may benefit 
more from minimally invasive surgery compared with other 
treatment options [86]. Candidates who can have the greatest 
benefit from minimally invasive procedures within the first 
72 hours from the onset of symptoms are patients of both 
sexes, aged 30-80 years, with superficial hematomas, GCS ≥ 
9, and a hematoma volume between 25-40 ml [86]. However, 
conventional craniotomy for hematoma evacuation maintains 
its actuality in patients with GCS between 4 - 8 at admission, 
those with large hematomas associated with cerebral edema or 
mass effect compressing the brain stem or centers that control 
vital functions etc [3, 87-89].
 Stereotactic evacuation and the method of puncture and 
aspiration with local fibrinolysis added new values to the 
minimally invasive techniques by allowing clot lysis inside 
the hematoma (using ultrasound waves or irrigation with 
fibrinolytic agents). Recent studies actually report that the 
enthusiasm for endoscopic aspiration seems to be declining 
in the context of emerged options allowing local instillation 
of fibrinolytic agents in the hematoma cavity for clot throm-
bolysis (streptokinase, urokinase, rTPA [65, 90]. The rate of 
reported favorable results of SICHs treated with stereotactic 
aspiration varies between 20.3% and 55.6% [74, 81, 91]. The 
puncture does not cause significant brain damage and acce-
lerates the recovery of cerebral function, avoiding the need 
for an open craniotomy or general anesthesia [37, 38]. An 
increasing number of studies have also shown that stereo-
tactic aspiration and local thrombolysis are safe and effective 
techniques in reducing the volume of SICHs [37, 85, 92]. 
However, none of these studies provided conclusive evidence 
for the choice of a treatment method according to patient’s 
clinical condition, hematoma location, neurological status 
and associated disorders [93, 94]. To answer these questions, 
a number of randomized clinical trials such as MISTICH or 
MISTIE have been started. The MISTICH (Minimally invasive 
surgery treatment for the Patients with spontaneous supra-
tentorial intracerebral hemorrhage) study is a multi-center, 
prospective, randomized, assessor-blinded, parallel group, 
controlled clinical trial that began in 2012 and was designed 
to determine whether minimally invasive surgeries could 
improve the prognosis for patients with SICHs compared with 
craniotomy [95]. The MISTIE (Minimally Invasive Stereotac-
tic Surgery plus recombinant tissue plasminogen activator for 
intracerebral hemorrhagic Evacuation) trial was designed to 
investigate the difference between surgical intervention plus 
rtPA and standard medical treatment for SICHs management 
[16, 80, 96, 97].  Preliminary results revealed that minimally-
invasive surgery plus rtPA shows greater clot resolution than 
traditional medical management. As a result of this, a phase 
II (MISTIE II) trial was designed to determine the safety and 
efficacy of using minimally invasive surgeries combined with 
rt-PA administration. A variety of other studies exploring 
new approaches and new avenues to improve the outcome of 
minimally invasive surgical techniques are also underway.
Surgical techniques applied  
in the Republic of Moldova
Neurosurgical institutions in Moldova have accumulated 
valuable experience in the treatment of supratentorial SI-
CHs, including minimally invasive techniques that are used 
worldwide. According to statistical data from the National 
Centre for Health Management, the incidence of intracerebral 
bleeding in Moldova comprised 677 cases in 2010, 632 cases 
in 2011 and 707 cases in 2012, with an average record of 672 
cases annually. According to the latest publications, SICHs 
(primary bleedings into the brain parenchyma without a 
known cause) represent 66% of intracerebral bleedings [58], 
and supratentorial SICHs represent about 86.7% of all SICHs 
[8]. Thus, the annual incidence in the Republic of Moldova 
represents about 447 cases of SICHs, from which 388 are 
supratentorial.
 According to institutional statistics reported by the In-
stitute of Neurology and Neurosurgery and the Institute of 
Emergency Medicine, only in these two institutions, during 
2011-2014 were performed 137 nerosurgical interventions for 
SICHs. From these, 67 interventions employed the puncture 
and aspiration technique with application of local fibrinolysis, 
and 70 interventions employed other minimally invasive tech-
niques or conventional craniotomy. Of note is that almost 50% 
of surgical interventions were performed using the puncture 
and aspiration with application of local fibrinolysis, which is 
one of the most advanced methods for treating SICHs at the 
international level. Moreover, some details of the technique 
were further refined by our experts, who obtained two paten-
ted inventions in this area.
An example of supratentorial SICH treated using the 
puncture and aspiration method with application of local 
fibrinolysis is shown in fig. 1. The technique can be divided 
into 4 steps: 
1.  Application of the burred hole. The procedure was 
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carrying out the procedure using a special device patented by 
our team (patented invention no. 824 of 11.06.2013).
2.  Puncture and drainage of intracerebral hematoma. 
Standard radiopaque silicone catheters for external ventri-
cular drainage can be also used for draining intracerebral 
hematomas. The catheters should have an internal diameter 
of 1.5 -2.5 mm, a 30 cm length, visible gradations at 5, 10 
and 15 cm, as well as additional side perforations at the blunt 
end of the catheter to increase the irrigation surface with a 
fibrinolytic agent. In some cases, a special intraoperative ne-
uronavigation system (SonoWand and Medtronic, USA, fig. 
2) was also employed. The neuronavigation system provides 
a higher precision and allows a more accurate placement of 
the catheter, which proved particularly useful for accessing 
small SICHs (≤30 ml) located deeply within basal ganglia.
3.  Aspiration of the liquid part of hematoma. In most 
cases, about 2-10 ml of the liquid content can be aspirated 
immediately after the puncture, depending on the evolution 
stage of hematoma. After aspirating the liquid content, the 
catheter is secured for subsequent fibrinolysis. An intra-
operative image of an inserted catheter is displayed in fig. 3. 
As the hematoma decreases in size, the catheter may require 
repositioning. A special guided catheter was developed for 
this purpose in the Institute of Neurology and Neurosurgery 
in Chisinau (patent invention no. 795 of 01.16.2014). The 
end of the catheter can change its direction at any angle, al-
lowing an easy re-positioning without the need for a surgical 
intervention.
Fig. 1.  Supratentorial  SICH treated using the puncture and aspiration technique with local fibrinolysis. A – preoperative images 
showing an intracerebral hemorrhage into the right cerebral hemisphere, B – estimation of the volume of hematoma, C – 3D computer 
modelling allowing calculation of the puncture trajectory and its correlation with external anatomical structures, D – postoperative 
images confirming the position of the catheter and post-therapy changes.
Fig. 2.  Intraoperative use of neuronavigation system 
(SonoWand, USA) in the Institute of Neurology and 
Neurosurgery in Chisinau.  The patient’s head is stabilized with 
rigid pinning fixation (Mayfield frame).
performed using preoperative CT images, allowing 3D mo-
delling of external anatomical landmarks (such as the external 
acoustic meatus and the lateral margin of the orbit). The 
calculations were subsequently applied intraoperatively for 
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Fig. 3.  An inserted catheter applied for external drainage of an 
intracerebral hemorrhage. Following the aspiration of the liqid 
part of hematoma, the catheter was secured.  A fibrinolytic agent 
is then injected through the catether in the hematoma cavity for 
local fibrinolysis of the remaining blood clots.
4.  Performing local fibrinolysis. A second-generation 
fibrinolytic agent – recombinant prourokinase (Hemaza) was 
administered for this purpose (5,000 IU every 6-10 hours). 
The number of procedures varied from 3 to 6 depending on 
the size of residual hematoma, with an average duration of 48 
hours. The decision to stop the fibrinolysis and remove the 
catheter was based on the follow-up CT scans.
 The obtained results showed many advantages of this te-
chnique such as: a lower rate and a reduced period of tracheal 
intubation, a lower rate of local postoperative complications, 
a reduced length of hospital stay, a lower overall mortality, a 
more frequent initiation of an early rehabilitation program 
with relatively better functional outcomes. The results are in 
agreement with those reported by many leading institutions at 
the European and international level. It should be noted that 
other treatment methods maintain their actuality depending 
on the type of hematoma and a variety of other factors, in-
cluding the bleeding size and location as well as the patient’s 
clinical condition and associated pathology. The experience 
gained in the Institute of Neurology and Neurosurgery allowed 
the development of a formal protocol for managing patients 
with suspected supratentorial SICHs that can be applied in 
neurological and neurosurgical units throughout the country 
(fig. 4). 
Conclusions and recommendations
1. All patients with symptoms suspicious for SICH 
require a complex assessment, regardless of hematoma stage. 
2. Consulting a neurologist or a neurosurgeon is man-
datory for detailed evaluation and for establishing an early 
treatment strategy.
3. Immediate admission of patients with SICHs in 
specialized ICU departments or Stroke units increases the 
chances for survival and for a better recovery of neurological 
deficits. 
4. After discharge from specialized institutions, pati-
ents with SICHs require periodic assessments at 1, 3, 6 and 
12-month intervals for detailed evaluation of their functional 
status, interval response to therapy and for preventing recur-
rences by controlling risk factors and associated diseases. 
Confirmation of SICH, with  
suspected vascular pathology 
(aneurism, AVM, cavernoma)
SICH confirmation with  
suspected brain tumor 
Confirmation of  primary 
supratentoreal SICH
SICH in basal ganglia or mixed 
location, > 3 cm from cortex 
surface, volume ≤ 30ml, 
GCS > 8
Worsening
Increase in volume, increasing 
shift of midline structures
Medical treatment
Head CT scan
Clinical suspicion of supratentoreal SICH (focal neurological deficits, 
headache, nausea, vomiting, nerve palsy, paresis)
Cerebral Angiography
Lack of underlying vascular 
pathology
Head MRI for staging and 
evaluation for surgical treatment
SICH of cortical, subcortical or 
mixed location, volume > 90ml, 
GCS ≤ 8, progressive 
deterioration
SICH of cortical, subcortical
or  basal ganglia localization, 
1-3cm from cortex surface, with 
a volume ≥ 30ml, minimal IVH 
and GCS ≥ 8
Puncture and aspiration with 
local fibrinolysis
Conventional open craniotomy
Control head CT scan
Fig. 4.  Developed protocol for managing patients with suspected supratentorial SICHs.
REvIEw ARTIClES Curierul medical, February 2016, Vol. 59, No 1
References
1. Reichart R, Frank S. Intracerebral Hemorrhage, Indication for Surgi-
cal Treatment and Surgical Techniques. Open. Crit. Care. Med. J. 
2011;4(1):68-71.
2. Aguilar MI, Freeman WD. Spontaneous intracerebral hemorrhage. Semin. 
Neurol. 2010;30(5):555-564.
3. Morgenstern L, Hemphill J, Anderson C, et al. Guidelines for the manage-
ment of spontaneous intracerebral hemorrhage: a guideline for healthcare 
professionals from the American Heart Association/American Stroke 
Association. Stroke. 2010;41(9):2108-29.
4. Beslac-BumbasIrevic L, Paden V, Jovanovic D, et al. Spontaneous intra-
cerebral hemorrhage. Period. Biol. 2012;114(3):337-45.
5. Hemphill JC, Greenberg SM, Anderson CS, et al. Guidelines for the 
Management of Spontaneous Intracerebral Hemorrhage: A Guideline 
for Healthcare Professionals From the American Heart Association/
American Stroke Association. Stroke. 2015;46(7):2032-60.
6. Aguilar MI, Brott TG. Update in intracerebral hemorrhage. Neurohospi-
talist. 2011;1(3):148-159.
7. Sacco S, Marini C, Toni D, et al. Incidence and 10-year survival of intrace-
rebral hemorrhage in a population-based registry. Stroke. 2009;40(2):394-
399.
8. Zurasky J, Aiyagari V, Zazulia A, et al. Early mortality following spontane-
ous intracerebral hemorrhage. Neurology. 2005;64(4):725-727.
9. Perez-Nunez A, Lagares A, Pascual B, et al. Surgical treatment for spon-
taneous intracerebral haemorrhage. Part I: supratentorial haematomas. 
Neurocirugia (Astur). 2008;19(1):12-24.
10. Mendelow AD, Gregson BA, Fernandes HM, et al. Early surgery versus 
initial conservative treatment in patients with spontaneous supratentorial 
intracerebral haematomas in the International Surgical Trial in Intracerebral 
Haemorrhage (STICH): a randomized trial. Lancet. 2005;365(9457):387-397.
11. Chan CL, Ting HW, Huang HT. The incidence, hospital expenditure, and, 
30 day and 1 year mortality rates of spontaneous intracerebral hemorrhage 
in Taiwan. J. Clin. Neurosci. 2014;21(1):91-94.
12. Domingues R, Rossi C, Cordonnier C. Diagnostic evaluation for nontrau-
matic intracerebral hemorrhage. Neurol. Clin. 2015;33(2):315-328.
13. Kelly ML, Sulmasy DP, Weil RJ. Spontaneous intracerebral hemorrhage 
and the challenge of surgical decision making: a review. Neurosurg. Focus. 
2013;34(5). article E1.
14. Elliott J, Smith M. The acute management of intracerebral hemorrhage: a 
clinical review. Anesth. Analg. 2010;110(5):1419-27.
15. Provencio JJ, Da Silva IR, Manno EM. Intracerebral hemorrhage: new chal-
lenges and steps forward. Neurosurg. Clin. N. Am. 2013;24(3):349-359.
16. Dey M, Stadnik A, Awad I. Spontaneous intracerebral and intraventricular 
hemorrhage: advances in minimally invasive surgery and thrombolytic 
evacuation, and lessons learned in recent trials. Neurosurgery. 2014;74(suppl. 
1):142-150.
17. Adeoye O, Broderick J. Advances in the management of intracerebral hemor-
rhage. Nat. Rev. Neurol. 2010;6(11):593-601.
18. Steiner T, Petersson J, Al-Shahi Salman R, et al. European research priorities 
for intracerebral haemorrhage. Cerebrovasc. Dis. 2011;32(5):409-419.
19. Feigin VL, Lawes CM, Bennett DA, et al. Worldwide stroke incidence and 
early case fatality reported in 56 population-based studies: a systematic 
review. Lancet. Neurol. 2009;8(4):355-369.
20. Thanvi B, Sprigg N, Munshi S. Advances in spontaneous intracerebral 
haemorrhage. Int. J. Clin. Pract. 2012;66(6):556-564.
21. Zis P, Leivadeas P, Michas D, et al. Predicting 30-day case fatality of primary 
inoperable intracerebral hemorrhage based on findings at the emergency 
department. J. Stroke. Cerebrovasc. Dis. 2014;23(7):1928-33.
22. Abraham M, Romano L, Latini F, et al. Supratentorial  correlation  of  age 
and  haematoma volume in patients with spontaneous  intracerebral hemor-
rhage. Neurol. Arg. 2014;6(1):23-28.
23. Ferrete-Araujo A, Egea-Guerrero J, Vilches-Arenas A, et al. Predictors 
of mortality and poor functional outcome in severe spontaneous intra-
cerebral hemorrhage: A prospective observational study. Med. Intensiva. 
2015;39(7):422-432.
24. Sampron N, Mendia A, Azkarate B, et al. Early mortality in spontaneous supra-
tentorial intracerebral haemorrhage. Neurocirugia (Astur). 2010;21(2):93-98.
25. Broderick J, Adams H, Barsan W, et al. Guidelines for the management of 
spontaneous intracerebral hemorrhage: A statement for healthcare profes-
sionals from a special writing group of the Stroke Council, American Heart 
Association. Stroke. 1999;30(4):905-915.
26. Caceres JA, Goldstein JN. Intracranial hemorrhage. Emerg. Med. Clin. North. 
Am. 2012;30(3):771-794.
27. O’Donnell M, Xavier D, Liu L, et al. Risk factors for ischaemic and intrace-
rebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a 
case-control study. Lancet. 2010;376(9735):112-123.
28. Zhang Y, Wang X, Schultz C, et al. Postoperative outcome of cerebral 
amyloid angiopathy-related lobar intracerebral hemorrhage: case series and 
systematic review. Neurosurgery. 2012;70(1):125-130.
29. Zazulia AR. Intracerebral Hemorrhage, Primary. Encyclop. Neurol. Sci. 
2014;2:734-741.
30. Dubourg J., Messerer M. State of the art in managing nontraumatic intra-
cerebral hemorrhage. Neurosurg. Focus. 2011;30(6). article E22.
31. Dye JA, Dusick JR, Lee DJ, et al. Frontal bur hole through an eyebrow inci-
sion for image-guided endoscopic evacuation of spontaneous intracerebral 
hemorrhage. J. Neurosurg. 2012;117(4):767-773.
32. Xi G, Strahle J, Hua Y, et al. Progress in translational research on intracerebral 
hemorrhage: is there an end in sight? Prog. Neurobiol. 2014;115:45-63.
33. Martínez-Domeño A, Martí-Fàbregas J. Hemorragia cerebral. Medicine. 
2015;11(71):4242-51.
34. Rivera L, Nekoovaght-Tak S, Saylor D, et al. Successful Management of 
Reversible Cerebral Vasoconstriction Syndrome-Induced Intracerebral 
Hemorrhage with Minimally Invasive Surgery Plus Recombinant Tissue-
Type Plasminogen Activator. J. Neurol. Stroke. 2014;1(5). article 00030.
35. Blacker D, Musuka T. Management of intracerebral hemorrhage in 2020. 
Future. Neurol. 2011;6(6):745-756.
36. Hou XY, Gao PY. Perihematomal perfusion typing and spot sign of acute 
intracerebral hemorrhage with multimode computed tomography: a pre-
liminary study. Chin. Med. Sci. J. 2014;29(3):139-143.
37. Wang JW, Li JP, Song YL, et al. Stereotactic aspiration versus craniotomy for 
primary intracerebral hemorrhage: a meta-analysis of randomized controlled 
trials. PLoS One. 2014;9(9). article e107614.
38. Zhou H, Zhang Y, Liu L, et al. Minimally invasive stereotactic puncture and 
thrombolysis therapy improves long-term outcome after acute intracerebral 
hemorrhage. J. Neurol. 2011;258(4):661-669.
39. Dowlatshahi D, Demchuk A, Flaherty M, et al. Defining hematoma ex-
pansion in intracerebral hemorrhage: relationship with patient outcomes. 
Neurology. 2011;76(14):1238-44.
40. LoPresti M, Bruce S, Camacho E, et al. Hematoma volume as the major 
determinant of outcomes after intracerebral hemorrhage. J. Neurol. Sci. 
2014;345(1-2):3-7.
41. Chan S, Hemphill J. Critical care management of intracerebral hemorrhage. 
Crit. Care. Clin. 2014;30(4):699-717.
42. Magistris F, Bazak S, Martin J. Intracerebral Hemorrhage: Pathophysiology, 
Diagnosis and Management. Clin. Rev. 2013;10(1):15-22.
43. Li Y, Zhang H, Wang X, et al. Neuroendoscopic surgery versus external 
ventricular drainage alone or with intraventricular fibrinolysis for intraven-
tricular hemorrhage secondary to spontaneous supratentorial hemorrhage: 
a systematic review and meta-analysis. PLoS One. 2013;8(11). article e80599.
44. Cutting S, Castro C, Lee V, et al. Impaired renal function is not associated 
with increased volume of intracerebral hemorrhage. J. Stroke. Cerebrovasc. 
Dis. 2014;23(1):86-90.
45. Jennett B. Development of Glasgow Coma and Outcome Scales. Nepal. J. 
Neurosci. 2005;2:24-28.
46. Barras C, Tress B, Christensen S, et al. Density and shape as CT predictors 
of intracerebral hemorrhage growth. Stroke. 2009;40(4):1325-31.
47. Du F, Jiang R, Gu M, et al. The accuracy of spot sign in predicting hematoma 
expansion after intracerebral hemorrhage: a systematic review and meta-
analysis. PLoS One. 2014;9(12). article e115777.
48. Park SY, Kong MH, Kim JH, et al. Role of ‘Spot Sign’ on CT Angiography to 
Predict Hematoma Expansion in Spontaneous Intracerebral Hemorrhage. 
J. Korean. Neurosurg. Soc. 2010;48(5):399-405.
49. Kidwell C, Wintermark M. Imaging of intracranial haemorrhage. Lancet. 
Neurol. 2008;7(3):256-267.
50. Broderick J, Connolly S, Feldmann E, et al. Guidelines for the management 
of spontaneous intracerebral hemorrhage in adults: 2007 update: a guide-
line from the American Heart Association/American Stroke Association, 
Stroke Council, High Blood Pressure Research Council, and the Quality of 
Care and Outcomes in Research Interdisciplinary Working Group. Stroke. 
2007;38(6):2001-23.
51
REvIEw ARTIClES
52
Curierul medical, February 2016, Vol. 59, No 1
51. Wijdicks EF. Clinical scales for comatose patients: the Glasgow Coma Scale in 
historical context and the new FOUR Score. Rev. Neurol. Dis. 2006;3(3):109-
117.
52. Rashid H, Amin R, Rahman A, et al. Correlation between intracerebral 
hemorrhage score and surgical outcome of spontaneous intracerebral 
hemorrhage. Bangladesh. Med. Res. Counc. Bull. 2013;39(1):1-5.
53. Ruiz-Sandoval J, Chiquete E, Romero-Vargas S, et al. Grading scale for 
prediction of outcome in primary intracerebral hemorrhages. Stroke. 
2007;38(5):1641-44.
54. Kasner SE. Clinical interpretation and use of stroke scales. Lancet. Neurol. 
2006;5(7):603-612.
55. van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for 
the assessment of handicap in stroke patients. Stroke. 1988;19(5):604-607.
56. Mahoney FI, Barthel DW. Functional evaluation: the Barthel index. State. 
Med. J. 1965;14:61-65.
57. Aguiar GB. Neurosurgical handling of spontaneous intracerebral hemor-
rhage - a review. Rev. Chil. Neurocirugía. 2013;39:38-44. 
58. Constantinescu A, Dănăilă L. Hematomul intracerebral spontan. Ghid de 
diagnostic şi tratament. [Spontaneous intracerebral hematoma. Guide for 
diagnosis and treatment]. http://www.usmf.md/Infomedica/documente/
Alre%20resurse/Ghiduri%20 medicale/ hematom_ic_spontan.pdf sau 
http://l.academicdirect.org/Medicine/Informatics /Evidence-Based/Guide-
lines/display/?gno=4 (citat 14.02.2014).
59. Maeda A, Aguiar L, Martins C, et al. Hematoma volumes of spontaneous 
intracerebral hemorrhage: the ellipse (ABC/2) method yielded volumes 
smaller than those measured using the planimetric method. Arq. Neurop-
siquiatr. 2013;71(8):540-544. 
60. Perez ES, Delgado-Mederos R, Rubiera M, et al. Transcranial duplex 
sonography for monitoring hyperacute intracerebral hemorrhage. Stroke. 
2009;40:987-990.
61. Cordonnier C, Klijn C, van Beijnum J, et al. Radiological investigation of 
spontaneous intracerebral hemorrhage: systematic review and trinational 
survey. Stroke. 2010;41(4):685-690.
62. Aguiar GB. Neurosurgical handling of spontaneous intracerebral hemor-
rhage - a review. Rev. Chil. Neurocirugia. 2013;39(1):38-44.
63. Delcourt C, Anderson C. Acute intracerebral haemorrhage: grounds for 
optimism in management. J. Clin. Neurosci. 2012;19(12):1622-26.
64. Teleanu DM, Constantinescu AI. Management of spontaneous intracerebral 
hemorrhage – a review. Roman. J. Neurol. 2014;13(1):12-16.
65. Naval NS, Nyquist PA, Carhuapoma JR. Advances in the management of 
spontaneous intracerebral hemorrhage. Crit. Care. Clin. 2006;22(4):607-617.
66. Gomes J, Manno E. New developments in the treatment of intracerebral 
hemorrhage. Neurol. Clin. 2013;31(3):721-735.
67. Anderson C, Heeley E, Huang Y, et al. Rapid blood-pressure lower-
ing in patients with acute intracerebral hemorrhage. N. Engl. J. Med. 
2013;368(25):2355-65.
68. Zheng J, Lin S, Li H, et al. Perioperative antihypertensive treatment in pa-
tients of spontaneous intracerebral hemorrhage (PATICH): a clinical trial 
protocol. Contemp. Clin. Trials. 2014;39(1):9-13. 
69. Li Z, Zhao X, Wang Y, et al. Association between seizures and outcomes 
among intracerebral hemorrhage patients: the China National Stroke Reg-
istry. J. Stroke. Cerebrovasc. Dis. 2015;24(2):455-464. 
70. Tapia-Pérez J, Gehring S, Zilke R, et al. Effect of increased glucose levels on 
short-term outcome in hypertensive spontaneous intracerebral hemorrhage. 
Clin. Neurol. Neurosurg. 2014;118:37-43.
71. Kellner CP, Connolly ES. Neuroprotective strategies for intracerebral hemor-
rhage: trials and translation. Stroke. 2010;41(10):99-102.
72. Lyden P, Shuaib A, Lees K, et al. Safety and tolerability of NXY-059 for acute 
intracerebral hemorrhage: the CHANT Trial. Stroke. 2007;38(8):2262-69.
73. Wang Y, Wu J, Mao Y, et al. The optimal time-window for surgical treatment 
of spontaneous intracerebral hemorrhage: result of prospective randomized 
controlled trial of 500 cases. Acta. Neurochir. 2008;105:141-145.
74. Chen X, Chen W, Ma A, et al. Frameless stereotactic aspiration and subse-
quent fibrinolytic therapy for the treatment of spontaneous intracerebral 
haemorrhage. Br. J. Neurosurg. 2011;25(3):369-375.
75. Newell D, Shah M, Wilcox R, et al. Minimally invasive evacuation of spon-
taneous intracerebral hemorrhage using sonothrombolysis. J. Neurosurg. 
2011;115(3):592-601.
76. Li G, Qin X, Pen G, et al. Effect of minimally invasive aspiration in treatment 
of massive intracerebral hemorrhage. Acta. Neurochir. 2011;111:381-382.
77. Wang T, Guan Y, Du J, et al. Factors affecting the evacuation rate of in-
tracerebral hemorrhage in basal ganglia treated by minimally invasive 
craniopuncture. Clin. Neurol. Neurosurg. 2015;134:104-109.
78. Xiao B, Wu F, Zhang H, et al. A randomized study of urgent computed 
tomography-based hematoma puncture and aspiration in the emergency 
department and subsequent evacuation using craniectomy versus craniec-
tomy only. J. Neurosurg. 2012;117(3):566-573.
79. Yang Z, Hong B, Jia Z, et al. Treatment of supratentorial spontaneous in-
tracerebral hemorrhage using image-guided minimally invasive surgery: 
Initial experiences of a flat detector CT-based puncture planning and 
navigation system in the angiographic suite. AJNR Am. J. Neuroradiol. 
2014;35911):2170-75.
80. Auer L, Deinsberger W, Niederkorn K, et al. Endoscopic surgery versus 
medical treatment for spontaneous intracerebral hematoma: a randomized 
study. J. Neurosurg. 1989;70(4):530-535.
81. Zuccarello M, Brott T, Derex L, et al. Early surgical treatment for supra-
tentorial intracerebral hemorrhage: a randomized feasibility study. Stroke. 
1999;30(9):1833-39.
82. Kirkman M, Mahattanakul W, Gregson B, et al. The effect of the results of the 
STICH trial on the management of spontaneous supratentorial intracerebral 
haemorrhage in Newcastle. Br. J. Neurosurg. 2008;22(6):739-746.
83. Steiner T, Al-Shahi Salman R, Beer R, et al. European Stroke Organisation 
(ESO) guidelines for the management of spontaneous intracerebral hemor-
rhage. World Stroke Organizat. 2014;9(7):840-855.
84. Potts MB, Riina HA. Refining the role for evacuation of spontaneous intra-
cerebral hematomas: results of STICH II. World. Neurosurg. 2014;82(5):549-
550.
85. Teernstra O, Evers S, Lodder J, et al. Stereotactic treatment of intracerebral 
hematoma by means of a plasminogen activator: a multicenter randomized 
controlled trial. Stroke. 2003;34(4):968-974.
86. Zhou X, Chen J, Li Q, et al. Minimally invasive surgery for spontaneous 
supratentorial intracerebral hemorrhage: a meta-analysis of randomized 
controlled trials. Stroke. 2012;43(11):2923-30.
87. Yang CD, Chen YW, Wu HC. Meta-analysis of randomized studies of surgery 
for supratentorial intracerebral hemorrhage. Formosan. J. Surg. 2014;47:90-
98.
88. Heuts SG, Bruce SS, Zacharia BE, et al. Decompressive hemicraniectomy 
without clot evacuation in dominant-sided intracerebral hemorrhage with 
ICP crisis. Neurosurg. Focus. 2013;34(5). article E4.
89. Fung C, Murek M, Z’Graggen W, et al. Decompressive hemicraniec-
tomy in patients with supratentorial intracerebral hemorrhage. Stroke. 
2012;43(12):3207-11.
90. Chang YH, Hwang SK. Frameless stereotactic aspiration for spontaneous 
intracerebral hemorrhage and subsequent fibrinolysis using urokinase. J. 
Cerebrovasc. Endovasc. Neurosurg. 2014;16(1):5-10.
91. Montes JM, Wong JH, Fayad PB, et al. Stereotactic computed tomographic-
guided aspiration and thrombolysis of intracerebral hematoma: protocol 
and preliminary experience. Stroke. 2000;31(4):834-840.
92. Sun H, Liu H, Li D, et al. An effective treatment for cerebral hemorrhage: 
minimally invasive craniopuncture combined with urokinase infusion 
therapy. Neurol. Res. 2010;32(4):371-377.
93. Prasad K, Mendelow A, Gregson B. Surgery for primary supratentorial in-
tracerebral haemorrhage. Cochrane. Database. Syst. Rev. 2009;1. CD000200.
94. Anik I, Secer H, Anik Y, et al. Meta-analyses of intracerebral hematoma 
treatment. Turk. Neurosurg. 2011;21(1):6-14.
95. Zheng J, Li H, Guo R, et al. Minimally invasive surgery treatment for the 
patients with spontaneous supratentorial intracerebral hemorrhage (MIS-
TICH): protocol of a multi-center randomized controlled trial. BMC Neurol. 
2014;14. article 206.
96. Mould W, Carhuapoma J, Muschelli J, et al. Minimally invasive surgery plus 
recombinant tissue-type plasminogen activator for intracerebral hemorrhage 
evacuation decreases perihematomal edema. Stroke. 2013;44(3):627-634.
97. Monteith S, Kassell N, Goren O, et al. Transcranial MR-guided focused 
ultrasound sonothrombolysis in the treatment of intracerebral hemorrhage. 
Neurosurg. Focus. 2013;34(5). article E14.
